SO-001D

SO-001D is a preclinical-stage small molecule derivative being developed by SOICUM (Socium) in collaboration with Nanjing Medical University. It is part of the SO-001 drug discovery program, which focuses on overcoming drug resistance to taxane-based anticancer agents. SO-001D is specifically designed to improve anticancer efficacy in taxane-resistant cancers, including prostate, breast, and uterine cancers. While the specific molecular target has not been publicly disclosed, the compound is categorized as a new chemical entity intended to restore sensitivity or provide alternative efficacy in tumors that have developed resistance to standard taxane therapies.